USD
( +0.00%
At Close (As of Jan 1, 1970)
$14.46M
Market Cap
-
P/E Ratio
-1.71
EPS
$10.40
52 Week High
$3.90
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $640K |
| Total Revenue | $7.8M |
| Cost Of Revenue | $7.2M |
| Costof Goods And Services Sold | $7.2M |
| Operating Income | -$9.8M |
| Selling General And Administrative | $7.8M |
| Research And Development | $7.2M |
| Operating Expenses | $10M |
| Investment Income Net | - |
| Net Interest Income | $467K |
| Interest Income | $467K |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $106K |
| Income Before Tax | -$9.6M |
| Income Tax Expense | -$9.6M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$9.6M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$7.1M |
| Ebitda | -$7M |
| Net Income | -$9.6M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $640K |
| Total Revenue | $7.8M |
| Cost Of Revenue | $7.2M |
| Costof Goods And Services Sold | $7.2M |
| Operating Income | -$9.8M |
| Selling General And Administrative | $7.8M |
| Research And Development | $7.2M |
| Operating Expenses | $10M |
| Investment Income Net | - |
| Net Interest Income | $467K |
| Interest Income | $467K |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $106K |
| Income Before Tax | -$9.6M |
| Income Tax Expense | -$9.6M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$9.6M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$7.1M |
| Ebitda | -$7M |
| Net Income | -$9.6M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Pulmatrix, Inc. is a clinical-stage biopharmaceutical firm based in Lexington, Massachusetts, specializing in the development of inhaled therapies aimed at treating respiratory diseases and serious conditions with significant unmet medical needs. Leveraging its proprietary inhalation drug delivery technologies, the company is advancing a robust pipeline of innovative treatments designed to improve patient outcomes and enhance quality of life. With a strategic commitment to key therapeutic areas, Pulmatrix is well-positioned to be a crucial contributor in the dynamic field of respiratory medicine.